0001104659-24-068503.txt : 20240605 0001104659-24-068503.hdr.sgml : 20240605 20240605071553 ACCESSION NUMBER: 0001104659-24-068503 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240604 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240605 DATE AS OF CHANGE: 20240605 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ArriVent BioPharma, Inc. CENTRAL INDEX KEY: 0001868279 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41929 FILM NUMBER: 241020711 BUSINESS ADDRESS: STREET 1: 18 CAMPUS BLVD. STREET 2: SUITE 100 CITY: NEWTOWN SQUARE STATE: PA ZIP: 19073-3269 BUSINESS PHONE: 240-780-6356 MAIL ADDRESS: STREET 1: 18 CAMPUS BLVD. STREET 2: SUITE 100 CITY: NEWTOWN SQUARE STATE: PA ZIP: 19073-3269 FORMER COMPANY: FORMER CONFORMED NAME: ArriVent Biopharma, Inc. DATE OF NAME CHANGE: 20210617 8-K 1 tm2416477d1_8k.htm FORM 8-K
false 0001868279 0001868279 2024-06-04 2024-06-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT 

Pursuant to Section 13 or 15(d) 

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 4, 2024

 

ARRIVENT BIOPHARMA, INC. 

(Exact name of registrant as specified in its charter)

 

Delaware   001-41929   86-3336099
(State or other jurisdiction
of incorporation)		   (Commission File Number)   (IRS Employer
Identification No.)

 

18 Campus Boulevard, Suite 100

Newtown Square, PA

   19073
(Address of principal executive offices)   (zip code)

 

Registrant’s telephone number, including area code: (628) 277-4836

 

N/A 

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading
Symbol(s)		   Name of each exchange
on which registered
Common Stock, $0.0001 par value per share   AVBP   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging Growth Company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

On June 4, 2024, ArriVent BioPharma, Inc. (the “Company”) entered into a Research and Collaboration Agreement with Jiangsu Alphamab Biopharmaceuticals Co., Ltd.  (“Alphamab”), a wholly owned subsidiary of Alphamab Oncology, pursuant to which the Company and Alphamab will discover, develop and commercialize novel antibody drug conjugates for the treatment of cancers (the “Alphamab Agreement”).

 

Under the Alphamab Agreement, and subject to the Company’s payment to Alphamab of the applicable research costs, Alphamab will grant the Company an exclusive, royalty-bearing, sublicensable license under certain Alphamab intellectual property and joint intellectual property to develop and commercialize such products in all fields of use worldwide, except greater China, which includes mainland China, Hong Kong, Macau and Taiwan (the “Retained Territory”). Alphamab retains the right to develop and commercialize such products in the Retained Territory. Under the Alphamab Agreement, the Company grants to Alphamab a royalty-free, perpetual license, which is exclusive during the term of the Alphamab Agreement and non-exclusive thereafter, under all intellectual property rights conceived, discovered, developed or otherwise made solely by the Company or jointly with Alphamab pursuant to the activities under the Alphamab Agreement for any and all purposes within the Retained Territory.

 

Upon commencement of activities to manufacture the products for use in certain clinical trials, Alphamab will grant to the Company a royalty-bearing license under certain Alphamab intellectual property to manufacture the applicable products. Under the Alphamab Agreement, Alphamab is entitled to an upfront payment and potential development and sales milestone payments of up to an aggregate of $615.5 million from the Company. Additionally, Alphamab is entitled to receive royalties in the low- to mid- single digit percent range on net sales of products outside greater China that may arise from the Alphamab Agreement.

 

The Alphamab Agreement is subject to termination (i) by either party for customary purposes, including the material breach by or bankruptcy of the other party, (ii) by the Company for convenience, (iii) by Alphamab due to the Company’s challenge of certain patents held by Alphamab, or (iv) by Alphamab on a product-by-product basis due to the Company’s failure to carry out certain diligence obligations or in certain instances if there is a change of control of the Company.

 

The foregoing summary of the Alphamab Agreement is qualified in its entirety by reference to the Alphamab Agreement, a copy of which the Company intends to file as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ending June 30, 2024.

 

Item 7.01 Regulation FD Disclosure.

 

On June 5, 2024, the Company issued a press release announcing the multi-target ADC collaboration with Alphamab. A copy of the press release is furnished as Exhibit 99.1 hereto.

 

The information set forth in this Item 7.01 and Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
99.1   Press Release dated June 5, 2024.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  ARRIVENT BIOPHARMA, INC.
     
  By: /s/ Winston Kung, MBA
    Winston Kung, MBA
    Chief Financial Officer and Treasurer

 

Date: June 5, 2024

 

  

 EX-99.1 2 tm2416477d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1 

 

 

 

ArriVent Announces a Multi-Target ADC Collaboration with Alphamab

 

Collaboration will leverage Alphamab’s antibody drug conjugate (“ADC”) research and discovery platform and ArriVent’s global development and commercialization expertise

 

Upfront and milestone payments to Alphamab worth up to $615.5 million for potential ADCs

 

SUZHOU, CHINA and NEWTOWN SQUARE, PA – June 5, 2024 – ArriVent BioPharma, Inc., (“ArriVent”) a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that the Company has entered into a collaboration agreement with Jiangsu Alphamab Biopharmaceuticals Co., Ltd. (“Alphamab”), a wholly owned subsidiary of Alphamab Oncology, to discover, develop and commercialize novel antibody drug conjugates (“ADCs”) for the treatment of cancers.

 

“This exciting collaboration strengthens and complements our pipeline with the potential to add multiple innovative new ADC programs and exemplifies our strategic model of identifying and developing potential first-and best-in-class product candidates from across the globe,” said Bing Yao, Chairman and Chief Executive Officer of ArriVent. “We look forward to complementing the research and discovery capabilities of Alphamab with our global drug development and commercialization expertise to address the unmet needs of cancer patients.”

 

“ArriVent shares our passion for developing differentiated, clinically valuable, and globally competitive new drugs," said Ting Xu, Ph.D., Founder, Chairman, and CEO of Alphamab Oncology. "This collaboration, based on Alphamab’s proprietary and clinically validated glycan-conjugation platform, combined with ArriVent’s deep knowledge in oncology and extensive development experience, provides us with the opportunity to work together to deliver important new oncology therapeutics to patients.”

 

Under the agreement, both companies will leverage Alphamab’s proprietary linker-payload platform and glycan-conjugation technology to identify novel ADCs for oncology indications. The agreement gives ArriVent exclusive rights to develop and commercialize ADCs globally, except greater China, which includes outside of mainland China, Hong Kong, Macau and Taiwan where Alphamab retains the right to develop and commercialize the ADCs.

 

The terms of the agreement include combined upfront and potential milestone payments to Alphamab of up to $615.5 million in aggregate for the potential programs, based on the achievement of certain regulatory, development, and sales milestones. In addition, Alphamab is entitled to receive tiered sales royalties from ArriVent for each ADC product.

 

About ArriVent

 

ArriVent is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. ArriVent seeks to utilize its team’s deep drug development experience to maximize the potential of its lead development candidate, firmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization.

 

1

 

 

 

 

About Alphamab Oncology

 

Alphamab Oncology is a leading biopharmaceutical company in China with a fully integrated proprietary biologics platform in bispecific and protein engineering. The Alphamab Oncology’s highly differentiated inhouse pipeline consists of monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates in staggered development status in oncology, including, among others, one approved for marketing by the National Medical Products Administration of China and three in late clinical stage. Alphamab Oncology has developed various technologies and platforms of antibody-based therapies for oncology treatment and expertise in this regard. Benefitting from the proprietary protein engineering platforms and structure-guided molecular modeling expertise, Alphamab Oncology is able to create a new generation of multi-functional biological drug candidates that could potentially benefit patients globally.

 

Forward-Looking Statements

 

This press release includes certain disclosures that contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding ArriVent’s ability to discover develop, and commercialize ADCs in collaboration with Alphamab, the potential milestone payments and tiered sales royalty payments to Alphamab, if any, the potential for such ADCs to help to address the unmet needs of cancer patients, the timing, progress and results of pre-clinical studies and clinical trials for any such ADCs, including our product development plans and strategies, ArriVent’s clinical programs, future results of operations or financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Forward-looking statements are based on ArriVent’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties that are described more fully in the section titled “Risk Factors” in ArriVent’s annual report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission on March 28, 2024, and its other filings with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and ArriVent undertakes no duty to update such information except as required under applicable law.

 

Contact for Investors & Media:

Argot Partners

212.600.1902

ArriVent@argotpartners.com

 

2

 

 EX-101.SCH 3 avbp-20240604.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 avbp-20240604_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 avbp-20240604_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2416477d1_ex99-1img001.jpg GRAPHIC begin 644 tm2416477d1_ex99-1img001.jpg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htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cover
Jun. 04, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 04, 2024
Entity File Number 001-41929
Entity Registrant Name ARRIVENT BIOPHARMA, INC.
Entity Central Index Key 0001868279
Entity Tax Identification Number 86-3336099
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 18 Campus Boulevard
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Newtown Square
Entity Address, State or Province PA
Entity Address, Postal Zip Code 19073
City Area Code 628
Local Phone Number 277-4836
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol AVBP
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://arrivent.com/role/Cover Cover Cover 1 false false All Reports Book All Reports avbp-20240604.xsd avbp-20240604_lab.xml avbp-20240604_pre.xml tm2416477d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2416477d1_8k.htm": { "nsprefix": "avbp", "nsuri": "http://arrivent.com/20240604", "dts": { "schema": { "local": [ "avbp-20240604.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "avbp-20240604_lab.xml" ] }, "presentationLink": { "local": [ "avbp-20240604_pre.xml" ] }, "inline": { "local": [ "tm2416477d1_8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://arrivent.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-06-04", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2416477d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-04", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2416477d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001104659-24-068503-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-068503-xbrl.zip M4$L#!!0 ( /HYQ5@FHQU_+ , .,+ 1 879B<"TR,#(T,#8P-"YX M],_T'U:\8V8)(F!)))TZ9#AC0=R*UYZ(",]JRJD[% H@&+,1TT++N>_9%[[+= MML#YV<:0&.'1J-1_8]A:Z#XB&C-]WVU/=%RECT7#=\7CL4#:"8\:' MP@E8M)U@3T*9B*E:):T4O^WH-U@$4_(!O#@3>O0V?+SN3;STV]U#5'^^O\Y#-D7P@B((5#.H M:%FZOJ*\L>

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tm2416477d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001868279 2024-06-04 2024-06-04 iso4217:USD shares iso4217:USD shares false 0001868279 8-K 2024-06-04 ARRIVENT BIOPHARMA, INC. DE 001-41929 86-3336099 18 Campus Boulevard Suite 100 Newtown Square PA 19073 628 277-4836 false false false false Common Stock, $0.0001 par value per share AVBP NASDAQ true false